Turnstone Biologics Corp.
TSBXDelisted Aug 11, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764974
Turnstone Biologics Corp. was delisted on Aug 11, 2025; its insiders filed their last Form 4 on Aug 12, 2025; 23 institutions reported holding it in 13F filings for Q2 2025, worth $3.03M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Turnstone Biologics Corp. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Turnstone Biologics Corp., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| OrbiMed Advisors LLC | Director | 0Indirect | Aug 12, 2025 | 0 |
| OrbiMed Capital GP VI LLC | Director | 0Indirect | Aug 12, 2025 | 0 |
| Versant Affiliates Fund V, L.P. | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Versant Venture Capital V, L.P. | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Versant Ophthalmic Affiliates I, L.P. | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Versant Venture Capital V (Canada), LP | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Versant Ventures V GP-GP (Canada), Inc. | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Versant Ventures V, LLC | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Versant Ventures V (Canada), L.P. | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Versant Vantage II, L.P. | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Versant Vantage II GP-GP, LLC | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Versant Vantage II GP, L.P. | 10% Owner | 0Indirect | Aug 12, 2025 | 0 |
| Gupta Rishi | Director | 0Indirect | Aug 8, 2025 | 0 |
| Jerel Davis | Director | 0Indirect | Aug 8, 2025 | 0 |
| Waddill William D. | Director | – | Jul 2, 2024 | 0 |
| Gould Robert J | Director | – | Jul 2, 2024 | 0 |
| Rajangam Kanya | Director | – | Jul 2, 2024 | 0 |
| FMR LLC | Other: See Remark 1 | 4,939Indirect | Jan 11, 2024 | 0 |
| Abbot Stewart | Chief Scientific Officer | – | Oct 17, 2023 | 0 |
| Burgess Michael F. | Interim Chief Medical Officer | – | Oct 17, 2023 | 0 |
| Campisi Peter Joseph Jr. | Chief Legal Officer | – | Oct 17, 2023 | 0 |
| Ramanan Venkat | Chief Financial Officer | – | Oct 17, 2023 | 0 |
| Azmat Saryah | Chief Business Officer | – | Oct 17, 2023 | 0 |
| Farah Sammy J. | President & CEO | – | Oct 17, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 27, 2023 (view filing)4:23 PM ET | Jul 25 | 2 days | Versant Affiliates Fund V, L.P. and 9 others10% Owner | PPurchase | +225.0K | $12.00 | +$2.70M | New position82.0K after | 4 lotsDuplicate filing |
| Jul 27, 2023 (view filing) | Jul 25 | 2 days | Jerel DavisDirector, 10% Owner | PPurchase | +225.0K | $12.00 | +$2.70M | New position82.0K after | 4 lots |
| Jul 24, 2023 (view filing)4:38 PM ET | Jul 20 | 4 days | OrbiMed Advisors LLC and 1 otherDirector, 10% Owner | PPurchase | +416.7K | $12.00 | +$5.00M | +15.5%3.10M after | Duplicate filing |
| Jul 24, 2023 (view filing) | Jul 20 | 4 days | Gupta RishiDirector, 10% Owner | PPurchase | +416.7K | $12.00 | +$5.00M | +15.5%3.10M after |